Literature DB >> 19276835

Predictors of surgery and consult with an oncologist for adjuvant chemotherapy in early stage NSCLC patients in Alberta, Canada.

Marcy Winget1, Jennifer Stanger, Zhiwei Gao, Charles Butts.   

Abstract

INTRODUCTION: In the fall of 2004, adjuvant chemotherapy for early stage non-small cell lung cancer (NSCLC) patients was approved for coverage by the Alberta Cancer Board, the provincial agency responsible for systemic therapy in the province of Alberta. The purpose of this study was to measure the proportion of early stage NSCLC patients diagnosed between 2004 and 2006 that received surgery and subsequently had a consult with an oncologist at a cancer facility, and to identify factors related to receiving surgery and having a consult that could be addressed.
METHODS: A retrospective observational study was conducted. All patients diagnosed with stage IB, IIA, or IIB NSCLC in Alberta from 2004 to 2006 were identified from the Alberta cancer registry. Date of definitive surgery, gender, age at diagnosis, and area of residence were also obtained from the cancer registry and evaluated as predictors for surgery and oncology consult. Date of consult with an oncologist was obtained from the electronic medical record of the Alberta Cancer Board.
RESULTS: There were 561 patients diagnosed with stage IB-IIB NSCLC from 2004 to 2006, 352 of whom had surgery and 255 of whom subsequently had a consult with an oncologist. Age and residence at diagnosis were both strongly associated with the likelihood of receiving surgery and the likelihood of attending a consult with an oncologist. DISCUSSION: Several areas of further research have been identified by this study including age and rural residence on treatment/referral patterns.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19276835     DOI: 10.1097/JTO.0b013e31819ccf26

Source DB:  PubMed          Journal:  J Thorac Oncol        ISSN: 1556-0864            Impact factor:   15.609


  7 in total

1.  Improving referral of patients for consideration of adjuvant chemotherapy after surgical resection of lung cancer.

Authors:  J A Zuccato; P M Ellis
Journal:  Curr Oncol       Date:  2012-12       Impact factor: 3.677

2.  Decision-making by surgeons about referral for adjuvant therapy for patients with non-small-cell lung, breast or colorectal cancer: a qualitative study.

Authors:  Robin Urquhart; Cynthia Kendell; Gordon Buduhan; Daniel Rayson; Joan Sargeant; Paul Johnson; Eva Grunfeld; Geoffrey A Porter
Journal:  CMAJ Open       Date:  2016-01-12

3.  Factors associated with referral to medical oncology and subsequent use of adjuvant chemotherapy for non-small-cell lung cancer: a population-based study.

Authors:  J Kankesan; F A Shepherd; Y Peng; G Darling; G Li; W Kong; W J Mackillop; C M Booth
Journal:  Curr Oncol       Date:  2013-02       Impact factor: 3.677

4.  Referral and treatment patterns among patients with stages III and IV non-small-cell lung cancer.

Authors:  Bernardo H L Goulart; Carolina M Reyes; Catherine R Fedorenko; David G Mummy; Sacha Satram-Hoang; Lisel M Koepl; David K Blough; Scott D Ramsey
Journal:  J Oncol Pract       Date:  2013-01       Impact factor: 3.840

Review 5.  Use of adjuvant chemotherapy in resected non-small cell lung cancer in real-life practice: a systematic review of literature.

Authors:  Anne-Laure Desage; Wafa Bouleftour; Olivier Tiffet; Pierre Fournel; Claire Tissot
Journal:  Transl Lung Cancer Res       Date:  2021-12

6.  Reasons for lack of referral to medical oncology for systemic therapy in stage IV non-small-cell lung cancer: comparison of 2003-2006 with 2010-2011.

Authors:  J J Ko; R Tudor; H Li; M Liu; K Skolnik; W Kells Boland; J Macklow; D Morris; D G Bebb
Journal:  Curr Oncol       Date:  2017-12-20       Impact factor: 3.677

7.  How do surgeons decide to refer patients for adjuvant cancer treatment? Protocol for a qualitative study.

Authors:  Robin Urquhart; Cynthia Kendell; Joan Sargeant; Gordon Buduhan; Paul Johnson; Daniel Rayson; Eva Grunfeld; Geoffrey A Porter
Journal:  Implement Sci       Date:  2012-10-25       Impact factor: 7.327

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.